Facebook
Twitter
LinkedIn
Forward
A New Wave of Systemic Treatments: Atopic Dermatitis, Meet JAK
Timely and adequate treatment of atopic dermatitis (AD) is essential for helping to promote better long-term outcomes and quality of life. Targeted immunomodulatory agents, based on recent advances in the understanding of AD pathophysiology, represent additional options for long-term control. In particular, Janus kinase (JAK) inhibitors have emerged as a novel mechanism of action for treatment of AD.
This enduring webinar activity is designed to provide guidance to clinicians who are in need of additional training to understand these new mechanisms of action and appropriate prescribing methods for emerging immunomodulatory therapies.
If you are less familiar with the pathogenesis or treatments of atopic dermatitis, please visit our educational primer and earn up to 0.25 CE Credits:
Target Audience
This activity is designed for an audience of US-based dermatologists and allergists, physician assistants, pharmacists and nurses who are in the care and treatment of patients with moderate to severe atopic dermatitis (AD).
Learning Objectives
- Interpret the efficacy and safety of current non-pharmacologic and pharmacologic treatments for AD and their limitations in long-term disease management
- Summarize the mechanisms of action and evidence with new and emerging targeted immunomodulatory agents for long-term AD management
- Develop individualized treatment plans for patients with moderate to severe AD that go beyond just treating flares and symptoms to optimize long-term control and overall quality of life
- Apply best practices for vaccination of immunocompromised patients with AD
- Introduction: Review of Primer
- Emerging Biologics for AD
- JAK Inhibitors in Atopic Dermatitis
- Altered Immunocompetence and Vaccination in AD Patients
- Conclusion/Q&A
Melinda Gooderham, MD
Medical Director, SKiN Centre for Dermatology
Assistant Professor, Department of Medicine
Queen’s University
Kingston, Ontario, Canada
Consultant Physician
Peterborough Regional Health Centre
Peterborough, Ontario, Canada
Brett King, MD, PhD
Associate Professor of Dermatology
Yale University School of Medicine
New Haven, Connecticut, United States
Kim Papp, MD, PhD, FRCPC
President and Director of Research
Probity Medical Research
Waterloo, Ontario, Canada
Disclosure of Conflicts of Interest
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Name of Faculty or Presenter | Reported Financial Relationship |
Melinda Gooderham, MD | Advisor - AbbVie Inc., Actelion Pharmaceuticals, AMGEN, Arena Pharmaceuticals, Asana Bio Sciences, Bausch Health, Boehringer Ingelheim International GmbH, Celgene Corporation, Dermavant, Eli Lilly and Company, Galderma SA., Janssen Inc., LEO Pharma, Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi Genzyme, Sun Pharmaceuticals and UCB. Consultant - AbbVie Inc., Akros Pharma Inc., AMGEN, Bausch Health, Boehringer Ingelheim International GmbH, Celgene Corporation, Dermavant , Eli Lilly and Company, Janssen Inc., Kyowa Kirin, Novartis Pharmaceuticals, Sanofi Genzyme, Sun Pharmaceuticals and UCB Contracted Research - AbbVie Inc., Akros Pharma Inc., AMGEN, Arcutis Pharmaceuticals Inc., Bausch Health, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Coherus Biosciences, Dermavant , Dermira Inc., Eli Lilly and Company, Galderma SA., GlaxoSmithKline, Glenmark, Janssen Inc., Kyowa Kirin, LEO Pharma, MedImmune, Merck and Co., Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Laboratories, Sanofi Genzyme, Sun Pharmaceuticals, Takeda Pharmaceuticals and UCB. Speaker - AbbVie Inc., Actelion Pharmaceuticals, AMGEN, Bausch Health, Boehringer Ingelheim International GmbH, Celgene Corporation, Dermavant , Eli Lilly and Company, Galderma SA., Glenmark, Kyowa Kirin, LEO Pharma, Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi Genzyme, Sun Pharmaceuticals and UCB. |
Brett King, MD | Advisory Board: AbbVie, AltruBio, Inc., Almirall, Arena Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Incyte Corp, Ostuska/Visterra Inc., Pfizer Inc., Regeneron, Sanofi Genzyme and Viela Bio Consultant: AbbVie, AltruBio Inc., Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Myers Squibb, Concert Pharmaceuticals, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra Inc., Pfizer Inc., Regeneron, Sanofi Genzyme, TWi Biotechnology Inc. Speaker: Pfizer Inc., Regeneron and Sanofi Genzyme |
Kim Papp, MD, Phd, FRCPC | Advisory Boards: AbbVie, Amgen, Astellas, Bausch Health/Valeant, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dice Pharmaceuticals, Dow Pharma, Galderma, Janssen, Merck (MSD), Novartis, PRCL Research, Regeneron, Sanofi-Aventis/Genzyme, Sun Pharma, UCB Consultant: AbbVie, Akros, Amgen, Arcutis, Astellas, Avillion, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Celitrion, Coherus, Dermava, Dermira, Dire Pharmaceuticals, Dow Pharma, Eli Lilly, Evelo, Forbion, Galapagos, Galderma, Genentech, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Meiji Seika Pharma, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Reistone, Roche, Sanofi-Aventis/Genzyme, Sandoz, Takeda, UCB, vTv Therapeutics, Xencor Clinical Research Grants: AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Avillion, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Coherus, Dermavant, Dermira, Dow Pharma, Eli Lilly, Evelo, Galapagos, Galderma, Genentech, Gilead, GKS, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Medimmune, Merck (MSD), Merck-Serono, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sub Pharma, Takeda, UCB Scientific Officer: Akros, Anacor, Arcutis, Dice Pharmaceuticals, Kyowa Hakko Kirin
Speakers Bureau: AbbVie, Amgen, Astellas, Baush Health/Valeant, Can-Fite Biophrama, Eli Lilly, Galderma, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Merck (MSD), Novartis, Pfizer, Sanofi-Aventis/Genzyme Steering Committee: AbbVie, Amgen, Bausch Health/Valeant, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Kyowa Hakko Kirin, Merck (MSD), Merck-Serono, Novartis, Pfizer, PRCL Research, Sanofi-Aventis/Genzyme |
Dorothy Caputo, MA, BSN, RN - AKH CE Director of Accreditations, has nothing to disclose.
Dorothy A. Duffy, RPh - AKH Pharmacy Reviewer, has nothing to disclose.
AKH Planners and Reviewers have no relationships to disclose.
The content manager, Amy Kousouros, from LivDerm, has nothing to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
Jointly provided by the AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio Inc. dba LivDerm
Estimated time to complete activity: 1 hour and 15 minutes
Commercial Support
This activity is supported by an educational grant from Incyte Corporation and Pfizer, Inc.
Physician Continuing Medical Education
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Credit being awarded: 1.25 ANCC contact hours
Physician Assistant Continuing Education
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Pharmacist Continuing Education
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.25 contact hour(s) (1.25 CEUs)
Type of Activity: Application
Internet
Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.
Hardware/Software Requirements
A computer or device with an internet connection.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Available Credit
- 1.25 AAPA Category I CME
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.